News

Dual HER2 targeting benefits OS of patients with advanced breast cancer


 

References

Adding pertuzumab to trastuzumab and docetaxel for treatment of HER2-positive metastatic breast cancer was more effective than adding a placebo to trastuzumab plus chemotherapy, according to Dr. Sandra M. Swain and her associates.

Dr. Sandra M. Swain

Dr. Sandra M. Swain

The median overall survival rate for the pertuzumab combination group was 56.5 months, while median survival time in the placebo group was 40.8 months. Median progression-free survival increased by 6.3 months, and the median duration of response was increased by 7.7 months. No significant difference in adverse events was found between the two groups.

While the results were promising, most of the deaths in the study were from breast cancer, indicating that better treatments are still needed. It is also “not clear whether hormonal therapy plus pertuzumab and trastuzumab is more effective than hormonal therapy plus trastuzumab alone in patients,” the investigators said.

Find the full study in the New England Journal of Medicine 2015;372:724-34 (doi:10.1056/NEJMoa1413513).

Recommended Reading

Breast cancer patients show poor adherence to cardiovascular, diabetes medications
MDedge Hematology and Oncology
Lung cancer bypasses breast cancer as leading cause of cancer death for women in developed countries
MDedge Hematology and Oncology
Controversy continues over platinum for TNBC patients
MDedge Hematology and Oncology
Stage trumps biology for most small triple-negative breast cancers
MDedge Hematology and Oncology
Smoking linked to many ‘new’ causes of death
MDedge Hematology and Oncology
Treatments for metastatic breast cancer expanding but decisions personalized
MDedge Hematology and Oncology
Cancer mortality lowest in western United States
MDedge Hematology and Oncology
Bevacizumab plus ET failed to improve PFS in HER2-negative, HR-positive BC
MDedge Hematology and Oncology
Joint breast and colorectal cancer screenings in medically underserved women
MDedge Hematology and Oncology
Perceptions about participation in cancer clinical trials in New York state
MDedge Hematology and Oncology

Related Articles